Results 71 to 80 of about 648 (164)

Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry

Therapeutic Advances in Neurological Disorders
Background: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice.
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C. Salmen, Ksenija Schirduan, Tom P. A. Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K. Zettl, Melanie Peters, Clemens Warnke   +14 more
doaj   +1 more source

Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review

CNS Neuroscience &Therapeutics, Volume 31, Issue 1, January 2025.
ABSTRACT Background Multiple sclerosis (MS) is an autoimmune disorder affecting the central nervous system, with varying clinical manifestations such as optic neuritis, sensory disturbances, and brainstem syndromes. Disease progression is monitored through methods like MRI scans, disability scales, and optical coherence tomography (OCT), which can ...
Armin Adibi, Iman Adibi, Milad Javidan
wiley   +1 more source

Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis [PDF]

Background: In recent years a broader range of immunomodulatory and immunosuppressive treatment options have emerged for people with progressive forms of multiple sclerosis (PMS).
Baldin E., Del Giovane C., Filippini G., Foschi M., Gonzalez-Lorenzo M., Minozzi S., Nonino F., Peryer G., Piggott T., Ridley B., Tramacere I.   +10 more
core   +1 more source

Cardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosis

Physiological Reports, Volume 12, Issue 24, December 2024.
Abstract Multiple sclerosis (MS) is a chronic neurological condition resulting in decreased aerobic capacity (peak VO2). The hemodynamic responses to peak exercise in MS are unknown. Further, it is unknown if the hemodynamic responses are due to disease or fitness.
Brooks A. Hibner, Natalia S. Lima, Sara R. Sherman, Robert W. Motl, Julio A. Chirinos, Shane Phillips, Philip S. Clifford, Anthony T. Reder, Tracy Baynard, Bo Fernhall   +9 more
wiley   +1 more source

COVID‐19 vaccination in patients with multiple sclerosis: what you need to know – a review

Health Science Reports, Volume 7, Issue 10, October 2024.
Abstract Background The appearance of severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2) initiated the COVID‐19 pandemic, resulting in millions of confirmed cases and numerous fatalities. In response, rapid vaccine development efforts were launched to mitigate the pandemic's impact.
Farhad Mahmoudi, Omid Mirmosayyeb, Elnaz Shaabani, Elham Moases Ghaffary, Flavia Nelson   +4 more
wiley   +1 more source

Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decreases ISR activation in DRG neurons

, 2023
AbstractDiabetic neuropathic pain is associated with elevated plasma levels of methylglyoxal (MGO). MGO is a metabolite of glycolysis that causes mechanical hypersensitivity in mice by inducing the integrated stress response (ISR), which is characterized by phosphorylation of eukaryotic initiation factor 2α (p-eIF2α). Nuclear factor erythroid 2-related
Muhammad Saad Yousuf, Marisol Mancilla Moreno, Jiahe Li, Lucy He, Danielle Royer, Jennifer Zhang, Brodie J Woodall, Peter M Grace, Theodore J Price   +8 more
openaire   +2 more sources

Shifting patterns of multiple sclerosis treatment in a highly prevalent United States population

Annals of Clinical and Translational Neurology, Volume 11, Issue 6, Page 1526-1534, June 2024.
Abstract Objective Our objectives were to (1) obtain the prevalence and demography of people with multiple sclerosis (MS) in a representative Colorado population, and (2) to assess the utilization of disease‐modifying therapy within this prevalent cohort.
Sue Kwon, Stefan Sillau, John R. Corboy, Kavita V. Nair, Aaron M. Carlson   +4 more
wiley   +1 more source

Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review

Clinical and Translational Science, Volume 17, Issue 5, May 2024.
Abstract No systematic review of trial designs in patients with relapsing multiple sclerosis (RMS) was reported. This systematic review was conducted on the trial designs and primary end points (PEs) of phase II and III trials intended to modify the natural course of the disease in patients with RMS. The purpose of the study is to explore trends/topics
Katsutoshi Hiramatsu, Hideki Maeda
wiley   +1 more source

De-escalating and discontinuing disease-modifying therapies in multiple sclerosis [PDF]

The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs after disease onset is associated with a better long ...
Amato, Maria Pia, Androdias, Géraldine, Audoin, Bertrand, Bruijstens, Arlette L, Bsteh, Gabriel, Butzkueven, Helmut, Ciccarelli, Olga, Cobo-Calvo, Alvaro, Derfuss, Tobias, Di Pauli, Franziska, Edan, Gilles, Enzinger, Christian, Geraldes, Ruth, Granziera, Cristina, Hacohen, Yael, Hartung, Hans-Peter, Hynes, Sinéad, Iacobaeus, Ellen, Inglese, Matilde, Kappos, Ludwig, Kuusisto, Hanna, Langer-Gould, Annette, Lünemann, Jan D, Magyari, Melinda, Maillart, Elisabeth, Marignier, Romain, Montalban, Xavier, Mycko, Marcin P, Nourbakhsh, Bardia, Oh, Jiwon, Oreja-Guevara, Celia, Piehl, Fredrik, Prosperini, Luca, Sastre-Garriga, Jaume, Sellebjerg, Finn, Selmaj, Krzysztof, Siva, Aksel, Stankoff, Bruno, Tallantyre, Emma, Tintoré, Mar, van Pesch, Vincent, Vukusic, Sandra, Weinstock-Guttman, Bianca, Zipp, Frauke   +43 more
core   +4 more sources

The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis

Journal of Immunology Research, Volume 2024, Issue 1, 2024.
Multiple sclerosis (MS) is a neurodegenerative autoimmune disease characterized by the destruction of the myelin sheath of the neuronal axon in the central nervous system. Many risk factors, including environmental, epigenetic, genetic, and lifestyle factors, are responsible for the development of MS.
Sujan Kumar Sarkar, Annie M. L. Willson, Margaret A. Jordan, Roberta Antonia Diotti   +3 more
wiley   +1 more source